stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) EBITDA
Travere Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$4.9M, compared with −$283.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$83.5M. Over the past ten years it has ranged from −$355.3M (fiscal 2023) to −$4.9M (fiscal 2025) — the current reading is the highest in ten years. Travere Therapeutics, Inc. ranks 396th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$4.9M | — |
| FY2024 | −$283.1M | — |
| FY2023 | −$355.3M | — |
| FY2022 | −$298.2M | — |
| FY2021 | −$173.4M | — |
| FY2020 | −$141.1M | — |
| FY2019 | −$82.3M | — |
| FY2018 | −$57.6M | — |
| FY2017 | −$34.0M | — |
| FY2016 | −$40.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$62.9M | — |
| Jun 2026 | $8.2M | — |
| Mar 2026 | −$11.7M | — |
| Dec 2025 | −$17.1M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$19.0M |
| TVTX Travere Therapeutics, Inc. | −$83.5M |
| MANE Veradermics Incorporated compare | −$88.4M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| DFTX Definium Therapeutics, Inc. compare | −$227.7M |
| DNTH Dianthus Therapeutics, Inc. compare | −$244.2M |
| ERAS Erasca, Inc. compare | −$302.6M |
| COGT Cogent Biosciences, Inc. compare | −$388.7M |
| CRSP CRISPR Therapeutics AG compare | −$513.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TVTX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement